LMDX

LumiraDx (LMDX)

LumiraDx Ltd

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:LMDX

1 2 3 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/01/06	07 : 45	GlobeNewswire Inc.	LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th	NASDAQ:LMDX	LumiraDx Ltd
2023/12/30	07 : 07	Dow Jones News	LumiraDx Agrees to Sell Point-of-Care Tech Platform to Roche	NASDAQ:LMDX	LumiraDx Ltd
2023/12/30	06 : 15	GlobeNewswire Inc.	LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche	NASDAQ:LMDX	LumiraDx Ltd
2023/10/28	05 : 45	GlobeNewswire Inc.	LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal	NASDAQ:LMDX	LumiraDx Ltd
2023/10/21	07 : 34	GlobeNewswire Inc.	LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England’s First Heart & Lung Screening Hub	NASDAQ:LMDX	LumiraDx Ltd
2023/08/24	20 : 45	GlobeNewswire Inc.	LumiraDx Reports Second Quarter 2023 Results	NASDAQ:LMDX	LumiraDx Ltd
2023/08/17	05 : 30	GlobeNewswire Inc.	LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24	NASDAQ:LMDX	LumiraDx Ltd
2023/07/31	19 : 00	GlobeNewswire Inc.	LumiraDx’s Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and Tests	NASDAQ:LMDX	LumiraDx Ltd
2023/07/01	04 : 26	Dow Jones News	LumiraDx Submits Dual FDA Medical Device Application for Covid-19 Test	NASDAQ:LMDX	LumiraDx Ltd
2023/07/01	03 : 30	GlobeNewswire Inc.	LumiraDx Submits First 510(k) Application to the FDA for COVID Ultra Test	NASDAQ:LMDX	LumiraDx Ltd
2023/06/21	05 : 15	GlobeNewswire Inc.	LumiraDx Receives UK CTDA Approval for COVID Ultra and COVID & RSV Tests	NASDAQ:LMDX	LumiraDx Ltd
2023/05/16	20 : 45	GlobeNewswire Inc.	LumiraDx Reports First Quarter 2023 Results	NASDAQ:LMDX	LumiraDx Ltd
2023/05/10	05 : 15	GlobeNewswire Inc.	LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 16	NASDAQ:LMDX	LumiraDx Ltd
2023/04/25	05 : 21	GlobeNewswire Inc.	LumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency	NASDAQ:LMDX	LumiraDx Ltd
2023/04/06	22 : 20	GlobeNewswire Inc.	LumiraDx Announces Strategic Refocus and Cost Restructuring Program	NASDAQ:LMDX	LumiraDx Ltd
2023/03/21	20 : 26	GlobeNewswire Inc.	LumiraDx Reports Fourth Quarter and Full Year 2022 Results	NASDAQ:LMDX	LumiraDx Ltd
2023/03/14	21 : 03	GlobeNewswire Inc.	LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21	NASDAQ:LMDX	LumiraDx Ltd
2023/03/03	23 : 00	GlobeNewswire Inc.	LumiraDx to Present at Raymond James Institutional Investors Conference	NASDAQ:LMDX	LumiraDx Ltd
2023/02/21	01 : 00	GlobeNewswire Inc.	LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements	NASDAQ:LMDX	LumiraDx Ltd
2023/02/06	22 : 59	Dow Jones News	LumiraDx Gets FDA Emergency Authorization for Dual Flu-COVID Test	NASDAQ:LMDX	LumiraDx Ltd
2023/02/06	22 : 00	GlobeNewswire Inc.	LumiraDx Receives FDA Emergency Use Authorization and UK CTDA Approval for its Fast Lab Solutions Multiplex COVID and Influenza Molecular Assay	NASDAQ:LMDX	LumiraDx Ltd
2023/02/01	06 : 30	GlobeNewswire Inc.	LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK	NASDAQ:LMDX	LumiraDx Ltd
2023/02/01	06 : 15	GlobeNewswire Inc.	LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency	NASDAQ:LMDX	LumiraDx Ltd
2022/12/14	17 : 19	GlobeNewswire Inc.	LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test	NASDAQ:LMDX	LumiraDx Ltd
2022/12/08	17 : 01	GlobeNewswire Inc.	Latest Clinicians’ U.S. Survey Identifies Point of Care Testing (POCT) as a Way to Address Healthcare Bandwidth Pressures and Anticipates Future Growth of POCT in Community Testing Centers	NASDAQ:LMDX	LumiraDx Ltd
2022/11/14	23 : 44	PR Newswire (US)	LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test	NASDAQ:LMDX	LumiraDx Ltd
2022/11/14	23 : 41	PR Newswire (US)	LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test	NASDAQ:LMDX	LumiraDx Ltd
2022/11/14	23 : 41	PR Newswire (Canada)	LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test	NASDAQ:LMDX	LumiraDx Ltd
2022/11/14	16 : 58	GlobeNewswire Inc.	LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test	NASDAQ:LMDX	LumiraDx Ltd
2022/11/14	13 : 05	TipRanks	LumiraDx (LMDX) Gets a Buy from BTIG	NASDAQ:LMDX	LumiraDx Ltd